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ABSTRACT
The objective of the  present  study was to prepare  microspheres with small size and good sphericity by spray drying 
technology using Isoniazid (INH) as model drug, chitosan as encapsulating polymer; lactose and L Leucine as bulking and 
dispersing agent respectively. Influence of formulation components on physical properties and aerosol performance were 
studied.  The  spray  dried  powders  obtained  were  characterized  for  morphological  characteristics,  compatibility  using 
scanning  electron  microscopy  and  Differential  Scanning  calorimetery  respectively.  Tapped  density;  bulk  density  and 
aerosol properties like Fine particle fraction, mass median aerodynamic diameter etc were also evaluated. The smooth 
microspheres with particle size ranging between 4 to 6 µm were obtained. The drug content of chitosan microspheres 
loaded with Isoniazid were in the range of 88 % to 108 %. The drug release studies showed that more than 90% of drug 
released from the chitosan microsphere matrix within one hour. The fine particle fraction observed between 55 to 67 % 
which indicate good lung deposition. Results of Fine particle fraction also revealed addition of L Leucine found to enhance 
powder dispersibility.
Keywords: Isoniazid, dry powder, L Leucine, Andersen cascade impactor, fin particle fraction.
INTRODUCTION
Inhalation therapy is widely employed to deliver drugs to the 
respiratory  epithelium,  predominately  for  the  treatment  of 
local  disorders  such  as  asthma  and  chronic  obstructive 
pulmonary  disease  (COPD),  although  there  is  increasing 
interest in using pulmonary delivery for the administration of 
systemically-acting macromolecules  like  inhaled insulin.
[1]
Pulmonary delivery systems have been widely applied in the 
treatment  of  pulmonary-related  diseases  to  reduce  side 
effects  of  systemic  administration  and  enhance  therapeutic 
effect  for  targeting  delivery.  Dry  powders  inhalers  are 
increasingly used for the aerosol delivery of drug to lung.
[2]
The development of antituberculosis formulation which can 
be  delivered  directly  to  the  lung  reduces  the  dose  and 
frequency  of  administration resulting  in  less  toxicity  and 
improvement in patient compliance. Targeting the drug to the 
alveolar  macrophage  may  improve  the  efficacy  and 
potentially reduce the systemic toxicity of the drug. The high 
drug concentration localized in the lung may reduce the 
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duration of treatment and prevent the multi-drug resistance of 
TB.
Particulate  characteristics  such  as  density,  particle  size, 
morphology,  surface  charge  and  drug  release  crucially 
influence pulmonary delivery. Certain approaches have been 
employed to improve powder aerosolisation such as mixing 
the  micronized  drug  with  inert  carrier  particles  or 
modification  of  particle  morphology,  particle  surface 
roughness,  particle  porosity  or  powder  density.
[3-9]  
Micronization of powder has been employed for preparation 
of  respirable  powders  having  particle  size  less  than  5µm. 
Although strong interparticluate cohesion is a leading cause 
for poor powder flow property which directly affects aerosol 
properties.
[10-11]
Spray-drying technology has potential to incorporate a range 
of excipients into the formulation to be spray-dried such as 
bulking agent and dispersibility enhancers (e.g. amino acids) 
[12-14] to  modify  the  aerosolisation  characteristics  of  the 
resultant  powder.  In  addition,  spray-dried  powders  that 
exhibit sustained drug release  properties may  be  generated 
through  the  inclusion  of  drug  release  modifiers  such  as 
hydroxypropyl  cellulose,  glyceryl  behenate  and  polylactic 
acid poly lactides.
[15-17] The particle size of the microspheres 
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microns  to  several  tens  of  microns  and  had  a  relatively 
narrow distribution.
[18]
Chitosan (CS), a polysaccharide derived from deacetylation 
of  the  naturally  occurring  polymer  chitin,  is  a  promising 
excipient  that  can  be  employed  in  a  wide  range  of
applications,  including  sustained  release  preparations. 
Indeed,  this  compound  has  received  considerable  attention 
for  the  formulation  of  spray-dried  powders  for  nasal  drug 
delivery. It has also been studied for inhalation drug, due to 
its biodegradability, biocompatibility and low toxicity.
[19-21]
There  are  number  of  advantages  to  developing  sustained 
release  formulation  using  chitosan  for  pulmonary  drug 
delivery, given that chitosan not only act release modifier but 
also  possess  a  mucoadhesive  properties.  Chitosan 
microspheres are most widely studied drug delivery systems 
for  the  controlled  release  of  drugs  viz.  antibiotics,  anti-
hypertensive  agents,  anti-cancer  agents,  anti-inflammatory 
agents, proteins, peptide drugs and vaccines.
[22]
The  purpose  of  the  present  study  was  to  prepare  chitosan 
microspheres by spray drying technique using L Leucine as a 
dispersing agent. Formulation factors  were investigated for 
physical properties such as particle size, surface morphology 
and  densities  of  chitosan  microspheres.  The  influences  of 
various particulate parameters were investigated in relation to 
aerosol performance and in-vitro drug release characteristics. 
The aim was to prepare chitosan microspheres loaded with 
Isoniazid as pulmonary delivery system which might enhance 
efficacy of Isoniazid for local antitubercular activity.  
MATERIAL AND METHODS
Isoniazid was obtained as a gift sample from Strides Acrolab, 
low molecular weight Chitosan was generously provided by 
C E Roeper Gmbh, Hamburg, and Germany. α, mono lactose 
was  received  as  gratis  sample  from  Meggle,  Wasserburg 
Gmbh  and  Co,  Germany.  L  Leucine  was  purchased  from 
Loba Chemicals India. All Other chemicals and solvents used 
were of analytical grade. 
Preparation of spray dried microspheres
Microspheres  were  prepared  by  spray  dried  technique.  In 
brief, 1% w/v Chitosan solution was prepared by dissolving 
chitosan  in  300ml  of  1%  acetic  acid  solution  at  50°C  by 
mechanical stirring). Isoniazid alone or in combination with 
lactose and L Leucine was dissolved in previously prepared 
and filtered chitosan solution. After adjusting the pH at 5, the 
drug chitosan solutions was stirred mechanically at 500 rpm 
for 20 minutes and then spray dried by LabUltima spray drier 
(LU-222  advanced.  Mumbai,  India)  with  standard  0.7  mm 
nozzle.  The  spray  drying  conditions  such  as  inlet 
temperature,  outlet  temperature,  pump  rate,  pressure  and 
aspirator setting were kept at 140°C, 70-80°C, 5 ml/min, 3 
kg/cm
2 and 45 m
3/hr respectively. 
Characterization of microspheres 
Spray dried yield and drug content
The  yield  of  spray  dried  product  was  identified  as  the 
percentage of anticipated yields. 
10 mg of drug loaded chitosan microspheres were dissolved 
in 50 ml of 0.1 N HCl. The solution was then passed through 
0.22 µm membrane filter (VWR international) and then the 
drug  content  was  assayed  by  measuring  the  absorbance  at 
264 nm after suitable dilution using UV spectrophotometer. 
The  experiment  was  carried  out  in  triplicate  (n=3)  and 
loading efficiencies were calculated according to following 
formula,  
Loading Efficiency = (calculated drug content/theoretical 
drug content) × 100
Scanning electron microscopy
Surface  morphology  of  spray  dried  chitosan  microspheres 
were obtained by using scanning electron microscope (ESEM 
TMP  with  EDAX,  Philips,  and  Holland).  Spray  dried 
powders were mounted onto separate, adhesive coated 12.5 
mm diameter aluminum stubs. Excess powder was removed 
by tapping the stubs sharply and then gently blowing a jet of 
particle  free  compressed  gas  across  each.  The  specimens 
were examined using EDAX SEM. The SEM was operated at 
high vacuum with accelerating voltage of 5KV and specimen 
working distance of 12mm. 
Differential scanning calorimetric characterization
Differential  scanning  calorimetery  pattern  of  the  samples
were obtained using Differential scanning calorimeter (DSC-
PYRIS-1, Perkin Elmer,USA). Each sample was heated from 
30 to 300°C  at scanning  rate  of 10°C  /min.  DSC analysis 
were  carried  out  on  blank  and  drug  loaded  chitosan 
microspheres. A physical mixture of the blank microspheres 
and the pure drug was used as control.
Particle Size
The particle size of the spray dried powder was measured by 
laser diffraction (HELOS particle size analyzer vibro/rodos 
dry  dispersion  system:  Sympatec  gmbh  system  partikel 
technik, Clausthal Zelerfeld, Germany). Approximately 100 
mg  of  each  powder  was  used  to  achieve  the  required 
obscuration  of  5%,  and  each  sample  was  measured  in 
triplicate. The data were expressed as the volume weighted 
mean particle size. 
Powder density and aerodynamic diameter 
The  poured  density  of  the  spray  dried  powder  was 
determined by pouring known mass of powder (0.5g) under 
gravity into a calibrated measuring cylinder and recording the 
volume occupied by the powder. The tapped density of spay 
dried  powder  was  determined  by  volume  measurement  of 
tapped mass until no further change a in the powder volume 
was  observed.  Measurement  was  performed  in  triplicate. 
Carr’s index values for each spray dried powder were derived 
from poured density data, according to following equation.
Carr’s Index = [1- (bulk density /Tapped density)] ×100
The Carr’s index values gives an indication of powder flow; 
a value less than 25% indicate a fluid flow, where as values 
greater than 25% indicates a cohesive powder.
[23]  
Theoretical estimation of the particle primarily aerodynamic 
diameter  dae was  derived  from the  sizing  (d50)  and tapped 
density data (p) according to following equation.
[24]
In vitro drug release studies
Dissolution testing was performed on a USP Type II tablet 
dissolution test apparatus (VEEGO) at a stirring speed of 150 
rpm. A dialysis membrane (Himedia, LA 401) was cut into 
equal  pieces  of  about  5  cm ×  3  cm  and  pre-treated  as 
suggested by the manufacturer. Microspheres (20 mg) were 
accurately weighed out on the pre-treated dialysis membrane 
and sealed with clips. The pouch thus formed was attached to 
the  paddles  of the  apparatus  using cotton threads  over the 
clips. 900 ml of phosphate-buffered saline at pH of 7.4 was 
used  as  a  dissolution  medium  to  ensure  sink  conditions. 
Samples  were  withdrawn  for  analysis  at  specified  time 
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spectroscopy (Shimadzu UV-1700, Japan) at 265 nm. Each 
dissolution experiment was performed in triplicate (n=3).
Characterization of Aerosol Performance
In vitro aerosolization properties of spray dried powders were 
investigated  by  using  Andersen  cascade  impactor  with 
preseparator  (Graseby- Andersen,  Atlanta,  GA,  USA) 
operating  at  air  flow  rate  of  60  L/min.  A  size  2,  HPMC 
capsules  were  obtained  from  Cipla  Ltd,  Mumbai.  The 
capsules were filled dry chitosan microspheres equivalent to 
10  mg  of  isoniazid.  Ten  capsules  were  shot  for  each 
impaction  at  inspiration  rate  of  with  60  L/min  for  an 
inhalation  time  of  10  seconds.  The  powder  deposited  in
induction port, preseparator, individual impaction plates and 
remaining in capsule and inhaler device  was recovered  by 
immersing each part in 0.1 N HCl. Drug concentration was 
determined  by  UV  spectrophotometer  (Shimadzu 
Corporation, Japan) after suitable dilutions at λmax 264 nm. 
Each measurement was taken in triplicate.
For each sample Emitted Dose (ED), Fine Particle Fraction 
(FPF),  experimental  Mass  Median  Aerodynamic  Diameter 
(MMADae) and Geometric Standard Deviation (GSD) was 
calculated. The emitted dose (ED) defined as the percentage 
of  total  loaded  powder  mass  exiting  the  capsule.  The fine 
particle  fraction  (FPF),  which  is  the  total  percentage 
deposition at stages 2–7 of the cascade impactor, was used to 
evaluate  the  aerosol  performance.  A  higher  fine  particle 
fraction  deposition  is  thought  to  indicate  a  higher  in  vitro 
aerosol  performance.  The  mass  median  aerodynamic 
diameter  (MMADae)  of  the  powders  was  also  derived, 
defined  as  the  particle  size  at  the  50%  mark  of  a  plot  of 
cumulative  fraction  vs.  effective  cut-off  diameter.  The 
geometric standard deviations (GSD) were obtained by the 
square root of the particle size at 84% cumulative divided by 
the 16% cumulative. 
RESULT AND DISCUSSION
Preparation of chitosan microspheres
The micro  encapsulation  technique  used  for  production  of 
entrapped  drug  particles  is  usually  efficient  not  only  for 
modification  of  drug  release  rate  but  also  for  temporary 
isolation  of  the  active  compound  from  surrounding 
environment. To optimize these functions, chitosan was used 
for encapsulation of drug as well as the particulate carrier for 
pulmonary  delivery  of  Isoniazid.  Chitosan  is  currently 
receiving a great deal of interest in pharmaceutical industry. 
Spray  drying  technique  is  a  well  known  process  which  is 
used to produce dry powders, granules or agglomerates from 
the  drug  –excipients  prepared  as  suspension,  emulsion  or 
solutions.
[25] The chitosan microspheres produced by spray 
drying method showed good narrow size distribution ranging 
from 4.27 µm to 6.01 µm. Since Isoniazid is a very water 
soluble drug the attempt was made to control the drug release 
from  the  chitosan  matrix.  The  L  Leucine  was  used  as 
antiadherant  to  improve  the  aerosol  dispersion  of  chitosan 
microspheres.  α-mono  lactose  was  used  as  bulk  forming 
agent.
Spray dried yield and drug content   
The spray dried yield of chitosan microspheres (yield, drug 
loading and encapsulation efficiency) loaded with the drug is 
presented in the Table 1. The yield percentage of the spray 
dried chitosan microspheres ranged from 16.4 ± 1.3 to 36.8 ± 
2.5 %. The addition of lactose and L Leucine in combination 
helped in getting higher yield by increasing the total content 
of mixture for spray drying. The chitosan microsphere yield 
without  the  bulking  and  dispersing  agent  ranged  between 
16.4 ± 1.3 to 26.1 ± 2.1 %. The relative lower yields were 
due to both the low quantity of the feed and the fact that the 
structure of the apparatus made it impossible to collect the 
smallest and lightest particles.
[26]
Table 1: Composition and characterization of spray dried chitosan 
microspheres (n=3)
Dry 
powde
rs
Drug
% 
w/v
Chitos
an
% w/v
L 
Leuci
ne
(mg)
Lacto
se
(mg)
% 
Yield
% 
Loading 
Efficiency
F1 0.20 1 - - 16.4 ± 
1.3
89.97± 
2.86
F2 0.30 1 - - 18.3 ± 
1.9
95.32 ± 
2.71
F3 0.40 1 -- - 23.8 ± 
2.2
94.44 ± 
2.01
F4 0.50 1 - - 26.1 ± 
2.1
92.90 ± 
3.26
F5 0.50 1 - 500 29.8 ± 
1.9
107.23 ± 
5.88
F6 0.50 1 500 - 30.7 ± 
1.1
89.53 ± 
1.96
F7 0.50 1 250 250 34.9 ± 
1.5
88.56 ± 
2.24
F8 0.50 1 335 165 33.8 ± 
2.1
87.34 ± 
3.22
F9 0.50 1 375 125 36.8 ± 
2.5
88.11± 
2.81
F10 0.50 1 400 100 36.5 ± 
3.3
93.62 ± 
2.80
Table 2: Aerosol properties of spray dried chitosan microspheres (n=3)
Dry 
powders
Particle size
D50
Tapped density
g/ml
Carr’s index
% MMADt
F1 5.65 ± 0.31 0.294 ±  0.02 42.2 3.06 ± 
0.16
F2 5.80 ± 0.29 0.245 ±  0.01 47.3 2.87 ± 
0.14
F3 6.01 ± 0.52 0.230 ±  0.02 45.4 2.88 ± 
0.25
F4 6.21 ± 0.43 0.289 ±  0.02 42.6 2.80 ± 
0.23
F5 4.58 ± 0.11 0.409 ±  0.03 39.5 2.45 ± 
0.06
F6 4.87 ± 0.24 0.288 ±  0.03 31.2 3.11 ± 
0.15
F7 5.46 ± 0.42 0.271 ±  0.02 36.1 2.42 ± 
0.21
F8 4.45 ± 0.31 0.241 ±  0.03 34.9 2.18 ± 
0.27
F9 4.40 ± 0.26 0.238 ±  0.04 36.2 2.14 ± 
0.19
F10 4.27 ± 1.21 0.196 ±  0.08 32.3 2.08 ±  
0.59
Table 3: Summary of aerosol deposition data of spray dried chitosan 
microspheres of selected formulations (n=3)
Dry 
powders
Emitted 
dose (ED)
FPF 
%
MMADt
(µ)
MMADae
(µ) GSD
F4 84.6 54.83 2.80 ± 0.23 3.85 2.44
F5 92.1 59.81 2.45 ± 0.06 3.64 2.29
F6 93.3 61.12 3.11 ± 0.15 3.48 2.80
F7 93.7 65.44 2.42 ± 0.21 3.44 2.59
F10 94.2 66.52 2.08 ± 0.59 2.71 1.92
*FPF= fine particle fraction, MMADt= theoretical mass median 
aerodynamic diameter, MMADae= Mass median aerodynamic diameter and 
GSD = Geometrical standard deviation
The % yield of spray dried  microspheres  was found to be 
increased when the drug concentration increased from 20 to 
50% w/w. Analysis of Isoniazid content of the spray dried 
powder indicated that the drug loading ranged from 88.56 ± 
2.24  to  107.23  ±  5.88.  However,  slight  yellowing  of  the Kundawala et al. / Influence of Formulation Components on Aerosolization Properties of Isoniazid…..……
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chitosan powders was observed on storage; this may be due 
to acid hydrolysis of lactose into glucose monosaccharide by 
residual acetic acid.
[27]
Fig. 1: Scanning electron micrograph of A) blank chitosan microspheres 
without additives B) drug loaded chitosan microspheres without 
additives C) chitosan microspheres with L Leucine and Lactose 
combination (ratio 4:1)
Scanning electron microscopy [SEM]
Scanning  electron  microscopy  was  used  to  visualize  the 
particle diameter, structural and surface morphology of the 
spray  dried  powder.  Photomicrograph  of  chitosan  loaded 
drug  particles  showed  regular  spherical  particle  with  a 
diameter  less  than  10µm.  The  unloaded  chitosan 
microspheres  had  comparatively  smooth  surface  to  drug 
loaded  microspheres  as  shown  in  Fig.  1(A).  The  chitosan 
microspheres  loaded  with  Isoniazid  exhibited  smooth  with 
irregular  depression.  The  aggregation  of  chitosan 
microspheres was also observed in micrograph that may be 
the result of drying conditions in spray drying process as seen 
in  Fig.  1(B,  C).  The  optical  microscopy  at  100  X  also 
indicates the aggregation formation of chitosan microspheres 
as shown in Fig. 5. 
Differential scanning calorimetric characterization 
DSC thermograms of pure drug , chitosan microspheres and 
physical  mixture,  D1,  D2  and  D3  shown  in  Fig.  2,  these 
result indicate that the pure drug D1 has shown endothermic 
peak at  173.27°C, which is due to the melting of drug. The 
thermograms of D2 has shown a slightly lesser intense peak 
at 172.197°C, the peak may be concentration dependent as it 
was in a physical mixture.  A broad peak at 125°C in the 
thermogram  of  D3  is  because  loss  of  associated  water. 
However,  sharp  peak  has  not  appeared  at  173°C  in 
thermogram D3 indicating the drug was in amorphous and 
complex form with the polymer, chitosan. 
Fig. 2: DSC thermogram of pure drug [D1], physical mixture with 
chitosan [D2] and chitosan microspheres [D3]
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Fig. 3: In vitro drug release of formulations F4 to F10 and of pure drug
Particle size analysis
Laser  diffraction  data  related  to  particle  size  analysis  are 
presented in Table 2. The particle size of each spray dried 
powders  was  less  than  10  µm  and  showed  D50  values  for 
smallest to largest particle ranging from 4.27±  1.21 µm to 
6.21 ± 0.43µm. It is interesting to note that the larger sized 
particles  may  be  resulted  due  to  the  higher  chitosan 
concentration  i.e.  1%  w/v employed  and  secondly  may  be 
due  to  the  powder  aggregation.  The  aggregation  was 
confirmed  from  SEM  micrographs,  where  chitosan 
microspheres  found  to  show  aggregation  of  particles.  The 
particles were seemed to be below <5 µm. as seen in Fig. 
1(B,  C).  The  result  of  optical  microscopy  and  SEM  also 
support  for  the  larger  particle  size  due  to  aggregation  of Kundawala et al. / Influence of Formulation Components on Aerosolization Properties of Isoniazid…..……
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microspheres it is in accordance with the reports suggested 
higher  chitosan  concentrations  produced  larger  sized 
microspheres  due  to  the  presence  of  a  greater  polymer 
amount in the same volume of a liquid droplet falling from 
spraying nozzle.
[27]
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Fig. 4:  Particle size distribution of spray dried powders on stages of 
ACI as aerosolized at flow rate of 60 L /min for selected Isoniazid 
formulations (F4-F8)
Fig. 5:  Optical Microscopic image of chitosan microspheres of 
formulation F8
Powder density and aerodynamic diameter
Carr’s Index may be used as an indication of powder flow 
properties; a value less than  25% indicates a fluid flowing 
powder, whereas a value greater than 25% indicates cohesive 
powder characteristics.
[28] The tapped density of spray dried 
powder varied from 0.196 ± 0.08 to 0.409 ± 0.03 g/cm
3. The 
Carr’s index was found to be in the range of 31.2 to 47.3 %. 
Larger  values  of  Carr’s  index  were  reflection  of  powder 
compaction offered by the fine particles.
In vitro drug release studies
In the absence of a more appropriate model, standard in vitro 
powder dissolution testing  was  used to provide dissolution 
profile pure drug and the spray-dried chitosan microspheres. 
The Isoniazid as pure drug found to get into the dissolution 
very  fast  within  5  minutes.  Chitosan  microspheres  loaded 
Isoniazid  showed  some  resistance  to  release.  All  the 
formulation  resulted  in faster dissolution greater than  90% 
released  in1  hrs.  The  burst  release  was  seen  in  all  the 
formulations  and slight higher  dissolution was  observed in 
case of formulation F5. The comparative release profile for 
formulations F4 to F10 is shown in Fig. 3. This kind of burst 
release  resulted  due  to  the  faster  swelling  of  spray  dried 
chitosan microspheres in dissolution medium. The faster drug 
release  also  attributes  towards  the  small  diffusion  path. 
Several investigators dealing with lower to higher molecular 
weight  chitosan  reported  that  increasing  the  amount  of 
chitosan and molecular weight increases the thickness of this 
diffusion layer, resulting in greater retention of drug release.
[28-30] In  our  studies,  we  maintained  a  constant  amount  of 
chitosan  in  the  formulations  i.e.  1  %  w/v  chitosan 
concentration. 
Aerosol performance of spray dried powder
Five selected formulations (F4- F8) were studied for emitted 
dose  (ED),  Fine  Particle  fraction  (FPF)  and  Mass  median 
Aerodynamic Diameter (MMADae) using Andersen Cascade 
Impactor (ACI). The data are displayed in Table 3. All the 
powders showed high emitted dose greater than 90% except 
the formulation F4 (84%).  The high dispersibility is clearly a 
reflection  of  inclusion  of  L  Leucine  as  a  dispersibility 
enhancer.
[31-33] The ACI mass deposition pattern for all the 
formulations under test is shown in Fig. 4. The small fraction 
of  deposition  in  device  and  throat  region  suggests  good 
deposition at central region of lung. The capsule and device 
retention  was  found  to  be  comparatively  higher  for 
formulation  F4.  The  result  showed  FPF  was  found  to  be 
increasing as the ratio of L Leucine to lactose changed from 
1:1 to 4:1. The FPF and emitted dose was increased from 54 
to 67 %: and 84 to 95 % respectively. For formulation F10 
the  %  FPF  (66.52  %)  was  marginally  higher  than  the  F4 
(54.83 %). The improvement of FPF  may be result of firstly, 
reduction in the capsule and device retention and/or secondly 
due  to  increase  in  the  powder  dispersibility,  that  is,  the 
amount  of  fine  particles  in  the  aerosol  cloud  per  emitted 
dose; which is probably because of combined role of their 
spherical shape, weak Vander Waals forces between them. 
Higher  mass  deposition  at  stage  1- 4 indicated  good 
deposition  in  central  to  lower  region  of  lung.  This  result 
suggests  possibility  of delivering fairly large  proportion of 
drug gets deposited to the central region of the lung. 
The MMADae for spray-dried powders were in the range of 
3.41  µm to  3.85  µm  was  slight  higher  in  line  with  the 
theoretical estimates of MMADt ranged between 2.08 µm to 
3.15  µm.  This  was  in  common  with  opinions  of  other 
investigators  who  have  noted  that  aerosolisation  of  spray-
dried powders can result in MMAD values much greater than 
the  theoretical  estimates  of  aerodynamic  diameter  derived 
from  powder density and  physical  diameter.  This behavior 
may  be  result  of  aggregation  of  particles  during 
aerosolisation  or  aggregated  particles.
[34] The  difference 
MMADt and MMADae value indicative of partial individual 
behavior  of  spray  dried  powders  rather  than  particle 
aggregates during aerosolisation. This may be due to the high 
proportion  of  L  Leucine in these  powders.  L Leucine is  a 
particularly  hydrophobic  amino  acid.  It’s  surfactant  like 
properties  may causes L Leucine to migrate to the droplet 
surface  during the rapid  drying phase in spray-drying, and 
hence  influence  the  surface  characteristics  of  the  resultant 
particle, 
[35-38] resulting  in  highly  dispersible  particles  that 
display  optimal  aerosolization  properties.  In  addition, 
researchers  have  shown  that  chitosan  can  enhance  the 
dispersibility of   spray-dried powders,
[39] and it is feasible Kundawala et al. / Influence of Formulation Components on Aerosolization Properties of Isoniazid…..……
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the chitosan is not only acting as a drug release modifier, but 
also  modifies  the  surface  of  the  particles,  decreasing 
interparticulate  cohesion  and  thereby  improving  powder 
dispersibility.
These  studies  on  spray  dried  chitosan  microspheres 
demonstrate that it is possible to generate highly respirable 
powders  that  exhibit  good  aerosolisation  properties.  It  is 
possible  to  produce  good  spherical  particles  with size  less 
than  10µm  with  spray  drying  technique,  suitable  for 
inhalation. Incorporation of larger dose is also possible with 
suitable  carrier  like  chitosan.  The  chitosan  microspheres
loaded  with  Isoniazid  was  found  to  possess  effective  fine 
particle fraction as well as lower impaction loss and device 
retention. In our study the incorporation of dispersing agents, 
L  Leucine  in  different  concentration  improves  the  aerosol 
performance  of chitosan  microspheres.  These  spray  dried 
microspheres would be predicted to deposit predominately in 
the  central  and  peripheral  regions  of  the  lung  following 
inhalation,  with  minimal  oropharyngeal  deposition  and 
maximizing the lung deposition efficiency.
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